Strides Shasun gets DCGI nod for manufacturing Hepatitis drug

Strides Shasun (earlier Strides Arcolab) has received Drug Controller General of India’s nod for manufacturing Virso, the generic version of Sofosbuvir 400 mg, the company said in an exchange filing. Sofosbuvir is used for the treatment of Hepatitis C. T

he drug combination therapy is shown to have high cure rate of around 90 per cent, according to the filing. In September 2014, Strides Arcolab had entered into a licensing agreement with Gilead Sciences Inc to bring the Hepatitis C cure to 91 developing countries. Shares of Strides Shasun gained 0.27 per cent at Rs..1,309.75 on the NSE.